Johnson & Johnson (NYSE:JNJ) Shares Sold by JSF Financial LLC

JSF Financial LLC decreased its position in Johnson & Johnson (NYSE:JNJFree Report) by 25.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,200 shares of the company’s stock after selling 1,453 shares during the period. JSF Financial LLC’s holdings in Johnson & Johnson were worth $654,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Diamant Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 1.0% in the third quarter. Diamant Asset Management Inc. now owns 23,091 shares of the company’s stock valued at $3,596,000 after acquiring an additional 226 shares in the last quarter. Milestone Investment Advisors LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $535,000. Fidelis Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 17.8% in the third quarter. Fidelis Capital Partners LLC now owns 13,181 shares of the company’s stock valued at $2,052,000 after acquiring an additional 1,992 shares in the last quarter. Pinnacle West Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 5.6% in the third quarter. Pinnacle West Asset Management Inc. now owns 14,620 shares of the company’s stock valued at $2,277,000 after acquiring an additional 775 shares in the last quarter. Finally, Austin Private Wealth LLC boosted its holdings in shares of Johnson & Johnson by 42.8% in the third quarter. Austin Private Wealth LLC now owns 8,695 shares of the company’s stock valued at $1,354,000 after acquiring an additional 2,604 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Tuesday, February 6th. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Morgan Stanley cut their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $176.14.

Get Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Up 0.2 %

Johnson & Johnson stock opened at $156.76 on Monday. The firm has a market cap of $377.37 billion, a PE ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm’s 50 day moving average price is $158.20 and its two-hundred day moving average price is $158.73. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.35 EPS. On average, research analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.